Multi-center clinical study to investigate the ratio of patients who have achieved Complete Molecular Response (CMR) with nilotinib treatment, among patients with chronic myelogenous leukemia in chronic phase who achieved Major Molecular Response (MMR) with imatinib treatment.
Phase of Trial: Phase II
Latest Information Update: 13 May 2016
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 23 Apr 2012 New trial record